The acquisition of Asklepios BioPharmaceutical (AskBio), while not a bargain, is a great move into the really hot topic of gene therapy. Based on the leading vector platform currently and pushed by numerous venture capital (VC) financing rounds, AskBio had built a broad and diversified R&D pipeline with three candidates in phase 1/2 trials. We see this as a major step towards better backward integration.

26 Oct 2020
A great move!
Bayer AG (BAYN:WBO), 0 | Bayer AG (BAYN:ETR), 0 | Bayer AG (BAYN.EUR:SWX), 0 | Bayer AG (BAYN:BSE), 0 | Bayer AG (BAYN:SWX), 0 | Bayer AG (0P6S:LON), 0 | Bayer AG (BAYER:BUD), 0 | Bayer AG (BAY:MIL), 0 | Bayer AG (BAYZF:OTC), 0 | Bayer AG (BAYNN:MEX), 0
-
-
-
Martin Schnee
-
3 pages
-


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A great move!
Bayer AG (BAYN:WBO), 0 | Bayer AG (BAYN:ETR), 0 | Bayer AG (BAYN.EUR:SWX), 0 | Bayer AG (BAYN:BSE), 0 | Bayer AG (BAYN:SWX), 0 | Bayer AG (0P6S:LON), 0 | Bayer AG (BAYER:BUD), 0 | Bayer AG (BAY:MIL), 0 | Bayer AG (BAYZF:OTC), 0 | Bayer AG (BAYNN:MEX), 0
- Published:
26 Oct 2020 -
Author:
Martin Schnee -
Pages:
3 -
The acquisition of Asklepios BioPharmaceutical (AskBio), while not a bargain, is a great move into the really hot topic of gene therapy. Based on the leading vector platform currently and pushed by numerous venture capital (VC) financing rounds, AskBio had built a broad and diversified R&D pipeline with three candidates in phase 1/2 trials. We see this as a major step towards better backward integration.